Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FATE $4.25 0.5450 +14.73%
ISIS $65.60 6.0500 +10.16%
ZIOP $4.69 0.4150 +9.72%
PBYI $228.10 19.4400 +9.32%
EPZM $19.97 1.6100 +8.77%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $6.14 -4.7100 -43.41%
GTXI $0.89 -0.0809 -8.34%
PARD $0.16 -0.0100 -5.88%
TLOG $4.78 -0.2700 -5.35%
CALA $27.59 -1.1601 -4.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

Florida Cancer Specialists & Research Institute Announces $2.5 Million Expansion of Corporate Headquarters

(FCS) Dec 3, 2014 - Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, announced a $2.5 million expansion of its corporate headquarters, located at 4371 Veronica S Shoemaker Blvd., Fort Myers, FL.
read corporate press release 



New York Oncology Hematology Terminates Contract With CDPHP

(Albany Business Review/Health Care Inc. blog) Dec 3, 2014 - New York Oncology Hematology, the Albany region's largest cancer-treatment practice, terminated its health insurance coverage agreement with CDPHP Wednesday, one of the largest insurers in the area.
read article 



Friends of Cancer Research and Brookings Institution Address Oncology Drug Development at a Conference on Clinical Cancer Research

(ASH) Dec 3, 2014 - The seventh-annual Conference on Clinical Cancer Research on November 21, 2014 brought together leaders in cancer drug development from federal, health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies.
read article 



AACR Applauds NCI's Bypass Budget

(AACR) Dec 3, 2014 - In the wake of budget cuts that have flat-lined funding for biomedical research for more than a decade, the American Association for Cancer Research (AACR) applauds this morning’s release of the National Cancer Institute’s (NCI) Professional Judgment Budget (“Bypass Budget”).
read press release 



Buckle Your Seatbelts: Cancer Centers Fly 'Very' Friendly Skies

(MedPage Today/The Gupta Guide) Dec 3, 2014 - You have just buckled in for your flight and you begin thumbing through the airline's magazine, when a series of articles on cancer treatment catches your eye.
read article (free registration required) 



New Drug 'More Effective' Than Chemo For Certain Patients With Advanced Lung Cancer

(Cancer Research UK/Press Association) Dec 4, 2014 - A new drug – crizotinib (Xalkori) – may be more beneficial than chemotherapy for some lung cancer patients, according to new research published in the New England Journal of Medicine.
read article 



Acetylon Pharmaceuticals Initiates Phase 2 Study of Ricolinostat (ACY-1215) in Combination With Pomalyst®

(4-traders) Dec 4, 2014 - Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced the initiation of a Phase 2 study of ricolinostat (ACY-1215), a selective HDAC6 inhibitor, in combination with Pomalyst® (pomalidomide, Celgene) for the treatment of relapsed-and-refractory multiple myeloma.
read article 



Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer

(Yahoo! Finance) Dec 3, 2014 - Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with nab-paclitaxel and gemcitabine, a current first line therapy, for the treatment of advanced pancreatic cancer.
read article 



PharmaMar Reports Phase IIb Results For PM1183 Showing a Median Overall Survival of 18.1 Months Compared to 8.5 Months For Topotecan in Platinum-Resistant Ovarian Cancer Patients

(PharmaMar) Dec 4, 2014 - Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.
read corporate press release 



New Study Refutes Pioglitazone and Bladder-Cancer Link

(Medscape Medical News) Dec 3, 2014 - An independent study carried out by a large research consortium has again found little evidence that cumulative exposure to pioglitazone causes bladder cancer in men or women.
read article (free registration required) 



Prostate Cancer Treatment Linked to Decreased Survival in Older Men

(Henry Ford Health System) Dec 3, 2014 - A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.
read press release 



Geography May Limit Access to Cancer Clinical Trials

(Reuters Health) Dec 3, 2014 - Where advanced cancer patients live affects the likelihood that they can enroll in a treatment clinical trial, a new study found.
read article 



Array Biopharma Regains Rights to Cancer Drug From Novartis

(TheStreet) Dec 3, 2014 - Array Biopharma is regaining full development and marketing rights to its experimental cancer drug binimetinib from Novartis, according to an agreement between the two companies announced Wednesday.
read article 



FDA Approves Blinatumomab For Relapsed or Refractory B-cell Precursor ALL

(ASCO in Action) Dec 4, 2014 - On December 3, 2014, the U. S. Food and Drug Administration granted accelerated approval for blinatumomab (BLINCYTOTM, Amgen Inc.) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL).
read article 



FDA Approves Jakafi to Treat Patients With a Chronic Type of Bone Marrow Disease

(FDA.gov) Dec 4, 2014 - The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease.
read press release 



Amgen Wins U.S. Approval for Drug to Treat Rare Leukemia

(Bloomberg) Dec 4, 2014 - Amgen Inc. won early U.S. approval for a drug that uses patients’ own immune systems to fight a rare form of leukemia as regulators seek to move quicker to provide potential treatments for unmet medical needs.
read article 



Array BioPharma to Regain Global Rights to Cancer Therapy From Novartis

(NASDAQ/Dow Jones Business News) Dec 3, 2014 - Array BioPharma Inc. said it reached a deal with Novartis AG under which the biopharmaceutical company will regain global rights to its binimetinib cancer treatment as well as an upfront payment of $85 million.
read article 



Pfizer's Xalkori Shows First-Line Benefit in ALK-Positive NSCLC

(PharmaTimes [UK]) Dec 4, 2014 - Pfizer’s targeted cancer therapy Xalkori (crizotinib) significantly extended progression-free survival in previously-untreated patients with a particular form of non-small cell lung cancer taking part in a late-stage trial compared to chemotherapy alone.
read article 



FDA Approves Blincyto to Treat a Rare Form of Acute Lymphoblastic Leukemia

(FDA.gov) Dec 3, 2014 - The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.
read press release 



Bayer CEO Happy to Have Fair Outcomes-based Pricing

(PharmaTimes [UK]) Dec 3, 2014 - Outcomes-based pricing holds no fears for Marijn Dekkers but the Bayer chief executive has urged governments to level the playing field when comparing old drugs with innovative products.
read article 



At N.I.H., Obama Stresses Need to Keep Funding Fight Against Ebola

(New York Times) Dec 2, 2014 - President Obama on Tuesday praised researchers for their progress in developing a potential vaccine for Ebola and called on Congress to pass $6.2 billion in emergency funds to fight the virus.
read article 



Novartis and Roche Suffer Setback in Italian Collusion Case

(Reuters) Dec 2, 2014 - Swiss drugmaker Novartis said a regional court in Italy had upheld a decision by Italian antitrust authorities which found Novartis and Roche colluded in anti-competitive practices.
read article 



FDA Considers Allowing Blood Donations From Some Gay Men

(NPR/Shots blog) Dec 2, 2014 - The Food and Drug Administration is considering revising a ban on blood donations from men who have had sex with other men. An FDA advisory committee Tuesday mulled the issues raised by changing the policy, which has been in effect since the early 1980s.
read article 



Sanofi Agrees €250m R&D Outsourcing Deal

(Financial Times) Dec 2, 2014 - Sanofi of France has entered exclusive talks over a €250m drug discovery alliance with Evotec of Germany aimed at increasing productivity from its research and development effort.
read article (free registration required) 



American Society of Hematology Honors Senator Barbara Mikulski and Patient Advocate Kathy Giusti

(ASH) Dec 2, 2014 - The American Society of Hematology (ASH) will recognize Senator Barbara Mikulski (D-MD) and Kathy Giusti, founder of the Multiple Myeloma Research Foundation, with awards for their outstanding support and advocacy for biomedical research and the practice of hematology at the 56th ASH Annual Meeting in San Francisco.
read press release